Tait Robert J, Teoh Lucinda, Kelty Erin, Geelhoed Elizabeth, Mountain David, Hulse Gary K
National Drug Research Institute, Faculty Health Science, Curtin University, Australia.
School of Psychiatry and Clinical Neurosciences, the University of Western Australia, Australia; School of Population Health, the University of Western Australia, Australia.
Drug Alcohol Depend. 2016 Aug 1;165:168-74. doi: 10.1016/j.drugalcdep.2016.06.005. Epub 2016 Jun 11.
Alcohol and other drug (AOD) use are significant cause of disease burden and costs among adolescents.
We conducted a randomized trial in hospital emergency departments (ED) following an AOD-related presentation, comparing usual care with brief advice and referral to link adolescents aged 12-19 years with external AOD services. Subsequently, we used health data linkage to assemble data on mortality, hospital admissions, ED attendances, out-patient mental health and use of opiate pharmacotherapies in the next 10 years. From these, treatment costs and rates of events were estimated and compared using generalized linear models.
Those who received the intervention had lower costs ($22 versus $227: z=3.16, p=0.002) and rates (0.03 versus 0.25: z=2.57, p=0.010) of ED mental health AOD presentations. However, the intervention did not significantly reduce overall mean health costs per patient (intervention $58746 versus control $64833, p=0.800). Similarly, there was no significant difference in the costs associated with hospitalizations ($48920 versus $50911 p=0.924), overall ED presentations ($4266 versus $4150, p=0.916), out-patient mental health services ($4494 versus $7717, p=0.282), or opiate pharmacotherapies ($1013 versus $2054, p=0.209). Injecting drug use was a significant baseline predictor of subsequent costs in the cohort (z=2.64, p=0.008).
An ED delivered intervention may reduce direct ED costs and subsequent ED AOD attendances. There was also some indication that overall costs may be impacted, with economically large but non-significant differences between the groups. The high costs and morbidity incurred by some of this cohort illustrate the importance of targeting high-risk adolescents.
酒精和其他药物(AOD)的使用是青少年疾病负担和成本的重要原因。
在因AOD相关就诊而前往医院急诊科(ED)的患者中进行了一项随机试验,将常规护理与简短建议及转介进行比较,以使12至19岁的青少年与外部AOD服务建立联系。随后,我们利用健康数据链接收集了未来10年的死亡率、住院情况、急诊科就诊情况、门诊心理健康状况以及阿片类药物治疗使用情况的数据。据此,使用广义线性模型估计并比较了治疗成本和事件发生率。
接受干预的患者急诊科心理健康AOD就诊的成本(22美元对227美元:z = 3.16,p = 0.002)和发生率(0.03对0.25:z = 2.57,p = 0.010)较低。然而,该干预措施并未显著降低每位患者的总体平均医疗成本(干预组58746美元对对照组64833美元,p = 0.800)。同样,在住院相关成本(48920美元对50911美元,p = 0.924)、总体急诊科就诊情况(4266美元对4150美元,p = 0.916)、门诊心理健康服务(4494美元对7717美元,p = 0.282)或阿片类药物治疗(1013美元对2054美元,p = 0.209)方面没有显著差异。注射吸毒是该队列后续成本的一个重要基线预测因素(z = 2.64,p = 0.008)。
急诊科实施的干预措施可能会降低急诊科的直接成本以及随后的急诊科AOD就诊率。也有一些迹象表明总体成本可能会受到影响,两组之间存在经济上较大但不显著的差异。该队列中一些患者产生的高成本和高发病率说明了针对高危青少年的重要性。